Group 1 - The core viewpoint of the news is the significant debut performance of two new pharmaceutical stocks, Baiaosaitu and Baoji Pharmaceutical, on their respective exchanges, reflecting strong market sentiment towards the biotech sector [1][2][3]. Group 2 - Baiaosaitu listed on the STAR Market and achieved a closing increase of 146.6%, with a total market capitalization of 29.41 billion yuan on its first trading day [2][4]. - Baoji Pharmaceutical debuted on the Hong Kong Stock Exchange, closing up 138.8% with a total market capitalization of 20.54 billion HKD [2][5]. - The overall performance of new pharmaceutical stocks in 2023 has been positive, with 8 new stocks listed in A-shares and 24 in Hong Kong, many of which saw their first-day gains exceed 100% [1][6]. Group 3 - Baiaosaitu has turned profitable in 2024, with projected revenues of approximately 9.8 billion yuan and a net profit of about 33.54 million yuan [4]. - In contrast, Baoji Pharmaceutical has not yet achieved profitability, with revenues of 6.93 million yuan in 2023 and projected losses of 1.6 billion yuan [5]. - The market's optimism towards the biotech sector is driven by expectations of high growth and the scarcity of new stocks, leading to significant investor interest [3][6].